Cohance Lifesciences Limited has announced two proposed transactions aimed at strengthening its antibody-drug conjugate (ADC) strategy, including an additional USD 13 million investment in NJ Bio and a USD 5 million controlling investment in Aruka Bio, Inc. Both transactions will be funded through internal accruals and are intended to establish clearer strategic priorities for the two businesses while expanding Cohance’s capabilities across the ADC value chain.
Under the proposed transaction, Cohance will increase its common-equity ownership in NJ Bio from 56.0% to 67.3% by acquiring the entire holdings of Ms. Priyashri Nayak and the Jain Family Irrevocable Trust. Dr. Naresh Jain will retain a 32.7% stake and will continue to lead NJ Bio during the transition while supporting the development of Aruka Bio’s proprietary pipeline and partnership initiatives.
NJ Bio will continue to focus on customer-facing contract research, development and manufacturing services. The closer integration with Cohance is expected to combine NJ Bio’s expertise in payload-linker chemistry and bioconjugation with Cohance’s manufacturing capabilities. This integrated model is designed to provide customers with broader support across the development cycle, from early-stage research and development through to commercial supply.
The proposed investment in Aruka Bio will give Cohance greater control over the company’s proprietary ADC platform. Based in Princeton, New Jersey, Aruka Bio is a privately held biotechnology company focused on developing next-generation antibody-drug conjugates. Its lead programme is currently at the preclinical stage.
Cohance’s USD 5 million equity investment in Aruka will support the buyout of existing shareholders and convertible noteholders, in addition to providing working capital for the company. Following completion of the transaction and an upfront equity grant to Dr. Jain, Aruka is expected to be owned 65% directly by Cohance, 25% by NJ Bio and 10% by Dr. Jain, before any further dilution resulting from Dr. Jain’s performance-linked equity award. Aruka will become a direct subsidiary of Cohance.
The reorganisation follows a review of NJ Bio’s performance and integration with Cohance since its initial investment in December 2024. The review identified opportunities to strengthen commercial alignment as NJ Bio expands its good manufacturing practice (GMP) contract development and manufacturing organisation (CDMO) services, while creating dedicated leadership focus for Aruka’s proprietary drug development pipeline.
Dr Naresh Jain, Founder and CEO of NJ Bio, said he would work across both businesses to support NJ Bio’s continued growth and an orderly leadership transition while collaborating with Cohance on advancing Aruka’s pipeline and identifying development partnerships. He is expected to subsequently focus full-time on Aruka as CEO while continuing to support NJ Bio as a strategic advisor.
Umang Vohra, Executive Chairman and Group CEO, Cohance Lifesciences, said the reorganisation provides each business with a distinct strategic focus by strengthening NJ Bio’s customer proposition through closer integration with Cohance and enabling Aruka to pursue the next stage of development under Dr. Jain’s leadership.
Cohance Lifesciences Limited is a technology-led, integrated CDMO platform that provides end-to-end development and manufacturing solutions across complex APIs, performance materials, agrochemicals, ADCs, oligonucleotides, and other advanced chemistries for global pharmaceutical and life sciences clients. Its expertise spans multi-step synthesis, high-potency APIs, controlled substances, flow chemistry, and continuous manufacturing, enabling it to support leading innovator and generic pharmaceutical companies across regulated markets worldwide. Cohance is publicly listed on India’s BSE and NSE and is majority owned by Advent.